Cardiac Ablation Articles & Analysis: Older
20 news found
(Company or Imricor) (ASX:IMR), the global leader in real-time iCMR cardiac ablation products, is pleased to announce that the Company has submitted for approval to commence a real-time iCMR-guided ventricular tachycardia (VT) ablation clinical trial. The name of the study is “Vision-MR Ablation of VT” or VISABL-VT. ...
ByImricor
The company anticipates final patient follow-up in June 2022 with Pre-Market Approval (PMA) submission of the AcQBlate FORCE sensing ablation catheter and system in the third quarter of this year. Designed specifically to provide consistent, effective therapeutic solutions during cardiac ablation procedures, the AcQBlate FORCE system shows ...
(Company or Imricor) (ASX:IMR) the global leader in Realtime iCMR cardiac ablation products, is pleased to announce it has entered into a Development Agreement with Mammendorfer Institut für Physik und Medizin GmbH (MIPM), a leading developer and manufacturer of MRI-compatible medical devices, including an MRI-compatible external cardioverter defibrillator. ...
ByImricor
(Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, today announced the scheduled retirement of its Chief Financial Officer, Ms Lori Milbrandt, and the appointment of Mr Jonathon Gut as the incoming Chief Financial Officer. ...
ByImricor
(Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, is pleased to announce that the Henry Dunant Hospital Centre in Athens, Greece (https://www.dunant.gr/en/) is the latest institution to adopt Imricor’s iCMR ablation solutions. ...
ByImricor
Adagio Medical, Inc., a leading innovator in catheter ablation technologies for atrial fibrillation (AF) and ventricular tachycardia (VT), today announced first-in-human cases of pulsed field cryoablation (PFCA) for the treatment of atrial fibrillation (AF). ...
(Company or Imricor) (ASX:IMR) the global leader in realtime iCMR cardiac ablation products, is pleased to announce that the German Heart Centre Berlin (https://www.dhzb.de/en/), and the Charité Medical University, Virchow-Klinikum Campus (Charité) (https://www.charite.de/en/), both in Berlin, Germany, are the latest two institutions to adopt ...
ByImricor
“Our vision for the future of this new energy source is to deliver it via a force sensing focal point ablation catheter and to guide that delivery with advanced 3D cardiac mapping, rather than fluoroscopy. ...
(Company or Imricor) (ASX:IMR) the global leader in iCMR-guided cardiac ablation products, is pleased to announce that the Semmelweis University Heart and Vascular Centre in Budapest Hungary, has signed a purchase agreement with Imricor, making it the eleventh site to establish an iCMR lab to perform ablations with Imricor’s products. ...
ByImricor
The acquisition will complement the existing Boston Scientific electrophysiology portfolio to include the FARAPULSE Pulsed Field Ablation (PFA) System – a non-thermal ablation system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. "The emerging field of PFA has the potential to alter the future of ...
VANCOUVER, British Columbia – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round. ...
SAN CARLOS, California, January 18, 2021 — Galaxy Medical, a developer of Pulsed Electric Field (PEF) technology for the treatment of cardiac arrhythmias, today announced that its proprietary CENTAURI™ System will be featured in a recorded case presentation on Sunday January 31st during the upcoming AF Symposium. ...
We are excited to be part of the further studies taking place with this AI software, as the VOLTA system may provide a major step forward in the effective approach to ablation of persistent AFib.” Conventional ablation methods, while useful for treating patients, who cannot tolerate or who are resistant to anti-arrhythmic drug therapy, have so far been ...
“Cardiac ablation is a large and growing market that faces significant challenges including disappointing clinical outcomes, long procedure times and unsatisfactory profitability for providers,” said Tuan Huynh. ...
The Centauri System is uniquely designed as an open energy platform utilizing a proprietary wave control algorithm enabling electrophysiologists to continue with the established point-by-point clinical workflow used in the majority of cardiac ablation procedures to deploy PEF energy to treat the widest array of patients with any lesion set. ...
Boston Scientific Corporation (NYSE: BSX) today announced it has signed an investment agreement with an exclusive option to acquire Farapulse, Inc., a privately-held company developing a pulsed field ablation (PFA) system for the treatment of atrial fibrillation (AF) and other cardiac arrhythmias. ...
This access site approach and size range is the standard in electrophysiology procedures such as cardiac ablation and left atrial appendage closure. In previous studies, VASCADE MVP has been proven to enable earlier ambulation, earlier discharge eligibility and higher patient satisfaction. The study is a prospective, multi-center, single arm registry that will ...
We are thrilled with the reception from physicians, and with the results we are seeing with this technology to help patients get back on their feet faster after procedures such as cardiac ablation and left atrial appendage closure.” The AMBULATE pivotal study is a randomized, controlled study of 204 patients across 13 sites treated with the VASCADE MVP ...
This access site approach and size range is the standard in electrophysiology procedures such as cardiac ablation and left atrial appendage closure. VASCADE MVP uses a simple and proprietary delivery system to place a collagen patch on the outside of each vessel puncture site following completion of the procedure. ...
Andrea Natale, executive medical director, Texas Cardiac Arrhythmia Institute. “The feedback from our patients and staff was extremely positive with VASCADE MVP during the study,“ said Dr. ...